Curium Announces Pharmacokinetics and Dosimetry Data for Investigational Lutetium-177 Zadavotide Guraxetan in Metastatic Castration-Resistant Prostate Cancer at ASCO GU 2026
Notified -
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2026-02-26, 22:00
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-02-17, 04:09
Predicine to Present Four Studies at 2023 ASCO
HAYWARD, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Predicine, a global molecular insights company, is committed to advancing genitourinary (GU) cancer...
